[LUTS in women and possible therapeutic effects of alfa1-adrenoblockers].
Lower Urinary Tract Symptoms (LUTS), including urinary incontinence, are one of the most common problems in women pathology.


OBJECTIVE
The objective of the authors is to determine the symptomatic index, to perform an urodynamic assessment and to establish the therapeutic possibilities of the alfa1-adrenoblokers in women with LUTS.


METHODS
In the course of a three year period (2001-2003) 74 women, ranging in age from 26 to 76 years old (average age of 48.6), have been examined and monitored. The symptomatic index was measured by a questionnaire, developed on the basis of IPSS and BFLUTS. The urodynamic study was performed with a multi-channel system Dantec-Meneut and includes multi-chanel cystrometry, followed by measuring of the pressure and the speed of urinary flow before the treatment and after it. Therapy with the L1-adrenoblocker Doxazosin was applied to 42 (56.7%) of the patients.


RESULTS
51 (68.9%) women were with predominantly irritative symptoms, and 23 (31.1%)--with predominantly obstructive. The urodynamic studies reval: 1. Obstruction of the lower urinary tract--7 (9.4%); 2. Obstruction with detrusor hyperactivity--15 (20.3%); 3. Detrusor hyperactivity--33 (44.6%); 4. Sensory urge-syndrome--6 (8.1%); 5. Disturbed contractility of the urinary bladder--4 (5.4%); 6. With no significant deviations--9 (12.2%) Total disappearance of the symptoms was achieved in 64.3% of the patients with the prescribed therapy, while in 11.9% symptoms have relapsed after discontinuation of the therapy.


CONCLUSIONS
LUTS in women is not only a gerontology problem. It affects more and more often women in active and child-bearing age. The therapeutic use of alfa1-adrenoblockers is one alternatives in the treatment of these patients.
Slavov
Ch
Ch
Dimitrov
R
R
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D017292:Doxazosin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism*; D014549:Urinary Incontinence / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D014554:Urination / Q000187:drug effects; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism
D000317:Adrenergic alpha-Antagonists; D018340:Receptors, Adrenergic, alpha-1; D017292:Doxazosin